A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
Condition(s) studied
Investigational drug(s) / intervention(s)
BG-75098: Administered orally.
BGB-43395: Administered orally.
Fulvestrant: Administered by intramuscular injection.
Study summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.
Eligibility
Primary outcome measure(s)
- Phase 1a: Number of Participants with Adverse Events (AEs) — From first dose to 30 days after last dose, up to approximately 12 months
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including physical examination findings, electrocardiogram results, laboratory values, and AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria. - Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-75098 — Up to approximately 2 years
MTD is determined based on a target for dose-limiting toxicities. MAD is defined as the maximum administered dose, and it is used when MTD is not reached. - Phase 1a: Recommended Dose(s) for Expansion (RDFE[s]) of BG-75098 as Monotherapy and in Combination with BGB-43395 and Fulvestrant — Up to approximately 2 years
The RDFE(s) will be determined from safety, tolerability, pharmacokinetic, pharmacodynamic biomarker(s), preliminary antitumor activity, and any other relevant data that are obtained from the dose escalation phase. - Phase 1b: Objective Response Rate (ORR) as Assessed by the Investigator — Up to approximately 2 years
ORR is defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR), as assessed by the investigator using RECIST v1.1.
Trial sites (23)
| Facility | City | Region | Status |
|---|---|---|---|
| University of Alabama At Birmingham Hospital | Birmingham | Alabama | Recruiting |
| City of Hope National Medical Center | Duarte | California | Recruiting |
| Yale Cancer Center | New Haven | Connecticut | Recruiting |
| Sidney Kimmel Comprehensive Cancer At Johns Hopkins | Baltimore | Maryland | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | Recruiting |
| The University of Texas Md Anderson Cancer Center | Houston | Texas | Recruiting |
| Next Oncology Houston | Houston | Texas | Recruiting |
| Medical College of Wisconsin | Milwaukee | Wisconsin | Recruiting |
| Blacktown Cancer and Haematology Centre | Blacktown | New South Wales | Recruiting |
| Genesiscare St Leonards | St Leonards | New South Wales | Recruiting |
| Icon Cancer Centre Wesley | Auchenflower | Queensland | Recruiting |
| Cabrini Hospital Malvern | Malvern | Victoria | Recruiting |
| Peter Maccallum Cancer Centre | Melbourne | Victoria | Recruiting |
| One Clinical Research | Nedlands | Western Australia | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing | Beijing Municipality | Recruiting |
| Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South) | Guangzhou | Guangdong | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin | Heilongjiang | Recruiting |
| Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology | Wuhan | Hubei | Recruiting |
| Union Hospital Tongji Medical College Huazhong University of Science and Technologyjinyinhu Branch | Wuhan | Hubei | Recruiting |
| Jiangsu Province Hospital Longjiang Branch | Nanjing | Jiangsu | Recruiting |
| Qilu Hospital of Shandong University | Jinan | Shandong | Recruiting |
| Weifang Peoples Hospital | Weifang | Shandong | Recruiting |
| Rigshospitalet | Copenhagen | Denmark | Recruiting |
More BeOne Medicines trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07226349 on ClinicalTrials.gov ↗ ← All trials in the USA